ASH 2015

The American Society of Hematology (ASH), the premier event for scientific exchange in the field of hematology, recently concluded its annual meeting in Orlando, Florida. Oral and poster presentations featured the latest research in malignant and non-malignant hematology that are considered the best of the thousands submitted for the annual meeting.

Meeting Highlights From ASH:

Acalabrutinib (ACP-196) Shows Efficacy, Safety in Adult CLL
Lauren Evoy Davis
December 15, 2015 | Hematologic Cancer Targets, ASH 2015
Acalabrutinib (ACP-196), a second-generation BTK inhibitor, has demonstrated high response rates in patients with chronic lymphocytic leukemia (CLL) who have experienced relapse or refractory disease.

Adding Rituximab to Chemotherapy Improves Outcomes for Adults With BCP-ALL
Lauren Evoy Davis
December 11, 2015 | ASH 2015, Hematologic Cancer Targets
During the plenary session at the American Society of Hematology’s (ASH) Annual Meeting on December 6, 2015, in Orlando, Fla., presenter Sébastien Maury, MD, PhD, had good news for the crowd anticipating the results of a multicenter trial.

Patients With B-Cell Malignancies Experience Remission After Allogeneic T-Cell Infusion
Lauren Evoy Davis
December 07, 2015 | ASH 2015, Cancer and Genetics, Hematologic Cancer Targets
A new study shows promise for patients with B-cell malignancies who receive allogeneic hematopoietic stem cell transplantation (alloHSCT).

Combination Therapy Promising for Newly Diagnosed Multiple Myeloma Patients
Lauren Evoy Davis
December 07, 2015 | ASH 2015, Hematologic Cancer Targets
Researchers have demonstrated in a phase II study, the efficacy of novel treatments for newly diagnosed multiple myeloma patients who are ineligible for stem cell transplantation.

– See more at: